SAMHSA Resources and Information
Training and Technical Assistance Related to COVID-19 (PDF | 198 KB)
This document is updated weekly with new training opportunities.
Disaster Distress Helpline
People feeling emotional distress related to COVID-19 can contact this helpline for support.
Learn more about SAMHSA’s COVID-19 funded grants.
- UPDATED: FY 2021 SAMHSA COVID-19 Funded Grants (PDF | 371 KB)
- UPDATED: FY 2020 SAMHSA COVID-19 Funded Grants (PDF | 340 KB)
- COVID-19 Emergency Response for Suicide Prevention Grants CLOSED
- Emergency Grants to Address Mental and Substance Use Disorders During COVID-19 CLOSED
- COVID-19 Information for SAMHSA Discretionary Grant Recipients
For behavioral health providers:
This document issued by CMS and SAMHSA provides information regarding expanding coverage for mental health and substance use disorder services delivered through telehealth platforms, telephone, and similar mechanisms to mitigate the impact of the COVID-19 public health emergency.
The document discusses the importance of Naloxone and a series of recommendations are provided to promote first responder safety during COVID-19.
This letter serves as confirmation from SAMHSA that the ordering of personal protective equipment, such as masks and gloves, by providers of mental and substance use disorder treatment services is for a legitimate need and purpose.
In response to COVID-19, SAMHSA provided this guidance to ensure that substance use disorder treatment services are uninterrupted during this public health emergency.
This document offers guidance to facilities, recommending that non-urgent visits be rescheduled, while also recommending that providers perform regular checks on patients at higher severity mental illness or substance use disorder.
Crisis centers that are able to remain operational and dispense medications to be administered unsupervised are asked to consider this guidance to minimize the potential for overdose and/or diversion.
Persons with Serious Mental Illness that are served in outpatient treatment settings may be at elevated risk for acquiring Covid-19 and may have a more complicated course. The Centers for Disease Control and Prevention (CDC) gives some specific guidance for outpatient facilities during the Covid19 emergency.
This document provides information regarding how to keep both patients and healthcare staff during COVID-19. Specific recommendations address how to reduce morbidity and mortality.
The DFWP highly recommends that agencies consult with their Office of Human Resources, Office of General Counsel and other appropriate offices prior to making telework related drug testing collection and testing decisions.
For general public:
This tip sheet describes resources that can be used to virtually support recovery from mental/substance use disorders. It also provides resources to help local recovery programs create virtual meetings.
This report highlights the health disparities that have been exacerbated as a result of COVID-19. In addition, recommendations are provided regarding what communities can do.
This brief discusses how COVID-19 may create safety concerns for victims of IPV during quarantine. In addition, several SAMHSA and non-SAMHSA resources are available.
Guidance for OTPs
- Opioid Treatment Program (OTP) Guidance (March 16, 2020) (PDF | 216 KB)
- OTP Guidance for Patients Quarantined at Home with the Coronavirus (PDF | 160 KB)
- FAQs: Provision of Methadone and Buprenorphine for the Treatment of Opioid Use Disorder in the COVID-19 Emergency (PDF | 202 KB)
- Sample OTP COVID-19 FAQs (PDF | 341 KB)
- Use of Telemedicine While Providing Medication-Assisted Treatment (PDF | 146 KB)